 SAN DIEGO, Sept. 20, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. 